Reasons to Hold Fresenius Medical Stock in Your Portfolio for Now
FMS's acquisitions, partnerships and global reach fuel growth, even as rising costs and optimization efforts weigh on near-term performance.
Here's Why Fresenius (FMS) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Fresenius Medical Care: 'Buy' Again Following A Peak In May
Fresenius Medical Care (FMS) is rated a 'Buy,' citing strong fundamentals. FMS demonstrates robust revenue growth, margin expansion, and dividend safety, with a new HVHDF product rollout expected to drive future upside. Despite market concerns over GLP-1 drugs and recent share declines, FMS is positioned for double-digit EPS growth and offers a well-covered 3-4% yield.
Why Fresenius (FMS) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
FMS Stock Rises as Q3 Earnings Beat Estimates, Revenues Gain Y/Y
Fresenius Medical Care's Q3 earnings and revenues beat estimates, fueled by margin gains and solid organic growth across segments.
Fresenius Medical Care beats quarterly profit estimates helped by cost cuts
Fresenius Medical Care reported a third-quarter operating income that exceeded analysts' expectations on Tuesday, in a sign that the dialysis specialist's cost-cutting measures were beginning to take hold.
CVS vs. FMS: Which Healthcare Services Stock Has More Upside?
CVS outpaces FMS in share gains and valuation appeal, with stronger earnings momentum and expanding health services driving its edge.
Reasons to Hold Fresenius Medical Stock in Your Portfolio for Now
FMS acquisitions, partnerships and global reach fuel growth, though rising costs weigh on near-term prospects.
Why Fresenius (FMS) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
FMS vs. OFIX: Which Stock Should Value Investors Buy Now?
Investors interested in Medical - Instruments stocks are likely familiar with Fresenius (FMS) and Orthofix (OFIX). But which of these two stocks presents investors with the better value opportunity right now?
FMS Stock Rises as Q2 Earnings Beat Estimates, Revenues Gain Y/Y
Fresenius Medical stock rises as Q2 earnings and revenues top estimates, driven by solid organic growth and expanding margins.
Fresenius Medical Care AG (FMS) Q2 2025 Earnings Call Transcript
Fresenius Medical Care AG (NYSE:FMS ) Q2 2025 Earnings Call August 5, 2025 8:00 AM ET Company Participants s - Corporate Participant o - Corporate Participant P - Corporate Participant Dominik Heger - Executive VP and Head of Investor Relations, Strategic Development & Communications Helen Giza - Chair of Management Board & CEO Martin Fischer - CFO & Member of the Management Board Conference Call Participants David James Adlington - JPMorgan Chase & Co, Research Division Falko Friedrichs - Deutsche Bank AG, Research Division Graham Doyle - UBS Investment Bank, Research Division Hassan Al-Wakeel - Barclays Bank PLC, Research Division Hugo Solvet - BNP Paribas Exane, Research Division James Alexander Stewart Vane- Tempest - Jefferies LLC, Research Division Oliver Metzger - ODDO BHF Corporate & Markets, Research Division Richard Felton - Goldman Sachs Group, Inc., Research Division Veronika Dubajova - Citigroup Inc., Research Division a divi - Unidentified Company ion - Unidentified Company f S& - Global Inc. All Rights reserved. Operator Ladies and gentlemen, welcome to the Report on Second Quarter 2025 Conference Call.
